Actively Recruiting
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
Led by AstraZeneca · Updated on 2026-04-20
200
Participants Needed
6
Research Sites
131 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations. The study will use standardized objectives, inclusion/exclusion criteria and outcome measures across all countries participating in this study including GCC (Qatar, KSA), Mexico, CAMCAR (Costa Rica, Panama, Dominican Republic), Colombia, Argentina, Taiwan, and Egypt, and any other countries that may be included in the study, in order to facilitate a comparison and analysis across all countries included in this study.
CONDITIONS
Official Title
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at study enrolment
- Diagnosed with SLE meeting the 2019 EULAR/ACR criteria
- First-time prescription of Anifrolumab for SLE according to country-specific approved label
- Physician decided to prescribe Anifrolumab before study discussion
- Required authorization for treatment access in countries with case-by-case reimbursement
- Provided informed consent to participate
- Willing and able to complete all study evaluations and procedures
You will not qualify if you...
- Currently in an Anifrolumab early access, compassionate use program, or interventional clinical trial
- Previous Anifrolumab exposure in a clinical trial or early access program
- Diagnosed with severe or rapidly progressive Class III or IV glomerulonephritis needing induction therapy, isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus
- Any condition limiting ability to understand informed consent or complete patient-reported outcomes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Research Site
Aktobe, Kazakhstan
Actively Recruiting
2
Research Site
Almaty, Kazakhstan
Actively Recruiting
3
Research Site
Astana, Kazakhstan
Actively Recruiting
4
Research Site
Pavlodar, Kazakhstan
Actively Recruiting
5
Research Site
Semey, Kazakhstan
Actively Recruiting
6
Research Site
Shymkent, Kazakhstan
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here